Citius Pharmaceuticals misses Q3 estimates with wider loss and lower revenue

Earnings
โดย Seeking Alpha·US·Read original
Summary · why it matters

Citius Pharmaceuticals reported fiscal third quarter 2026 results that fell short of expectations. GAAP EPS came in at a loss of $0.34, missing by $0.09, while revenue of $1.5 million missed by $8.27 million. The company had cash and cash equivalents of $17.0 million as of June 30, 2026.

Impact on stocks 1

Biotech & Genomic Medicine▼ · 1 stocks
© 2026 MarketDXNews